Recent Updates
Recently added Catalysts

Acetylcystine

Phase 3

Common Cold | Small molecule | Other |GSK plc|Last Updated: Jan 31, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment58
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02822287Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive CoughPHASE3 COMPLETED 58Feb 1, 2016Mar 1, 2016Jan 31, 20171 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Onset of Warming Sensation
10 minutes post-dose

Onset and duration of action of warming sensation was measured by two stop watches started when the participants took the oral solution. First watch was stopped at the start of warming sensation and the second watch was stopped at the end. If onset had not occurred by 10 minutes then time to onset was censored at 10 minutes. 53 of the 57 participants had onset within 10 minutes after dosing.

Duration of Warming Sensation
10 minutes post-dose

Duration of action of warming sensation was measured by two stop watches started when the participants took the oral solution. First watch was stopped at the start of warming sensation and the second watch was stopped at the end. If onset of warming sensation occurred within 10 minutes of dosing but had not ended by the end of 10 minutes following dosing, then the duration was censored at 10 minutes minus the time to onset

Warming Sensation Intensity at Pre-Dose and 60 Sec (Seconds) Post-Dose
Pre-dose and 60 sec post-dose

Warming Sensation Intensity was measured on 100 mm visual analogue scale (VAS), marked as "no warming sensation" on the left hand side (= 0 mm) and "strongest possible warming sensation" at the right hand side (=100 mm) at pre-dose.

Secondary Endpoints
Number of Participants With Acceptability of Warming Sensation
10 minutes post-dose
Number of Participants With Overall Opinion of Warming Sensation
10 minutes post-dose
Number of Participants With Overall Opinion of Oral Solution
1 hour post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
2% Acetylcystine SolutionEXPERIMENTALParticipants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
Interventions
NameTypeDescription
AcetylcystineDRUGClear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Participants must give written informed consent before any assessment is performed. In the case of adolescents Informed Consent must be signed by one or both parents or legal guardian as per local regulations and an Informed Assent must be signed by the participant. * Must be ...

Countries:Germany
Unlock Eligibility Criteria